                         SEQUENCE LISTING

<110>  Amgen Research (Munich) GmbH
 
<120>  Prevention of adverse effects caused by EpCAMxCD3 bispecific 
       antibodies

<130>  MIM14366PCT

<150>  US 61/569,180
<151>  2011-12-09

<160>  7     

<170>  PatentIn version 3.5

<210>  1
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SEQ ID NO: 88 of WO 2005/040220 (CDR-H1 of CD3 binding domain)

<400>  1

Gly Tyr Thr Phe Thr Arg Tyr Thr Met His 
1               5                   10  


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SEQ ID NO: 92 of WO 2005/040220 (CDR-H2 of CD3 binding domain)

<400>  2

Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SEQ ID NO: 96 of WO 2005/040220 (CDR-H3 of CD3 binding domain)

<400>  3

Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr 
1               5                   10  


<210>  4
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SEQ ID NO: 100 of WO 2005/040220 (CDR-L1 of CD3 binding domain)

<400>  4

Arg Ala Ser Gln Ser Val Ser Tyr Met Asn 
1               5                   10  


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SEQ ID NO: 102 of WO 2005/040220 (CDR-L2 of CD3 binding domain)

<400>  5

Asp Thr Ser Lys Val Ala Ser 
1               5           


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SEQ ID NO: 104 of WO 2005/040220 (CDR-L3 of CD3 binding domain)

<400>  6

Gln Gln Trp Ser Ser Asn Pro Leu Thr 
1               5                   


<210>  7
<211>  515
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SEQ ID NO: 63 of WO 2005/040220 (=MT110)

<400>  7

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 
1               5                   10                  15      


Val His Ser Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val 
            20                  25                  30          


Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu 
        35                  40                  45              


Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys 
    50                  55                  60                  


Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu 
65                  70                  75                  80  


Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe 
                85                  90                  95      


Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr 
            100                 105                 110         


Cys Gln Asn Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys 
        115                 120                 125             


Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
    130                 135                 140                 


Gly Gly Ser Glu Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Leu Val 
145                 150                 155                 160 


Arg Pro Gly Thr Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala 
                165                 170                 175     


Phe Thr Asn Tyr Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly 
            180                 185                 190         


Leu Glu Trp Ile Gly Asp Ile Phe Pro Gly Ser Gly Asn Ile His Tyr 
        195                 200                 205             


Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser 
    210                 215                 220                 


Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Phe Glu Asp Ser Ala 
225                 230                 235                 240 


Val Tyr Phe Cys Ala Arg Leu Arg Asn Trp Asp Glu Pro Met Asp Tyr 
                245                 250                 255     


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser 
            260                 265                 270         


Asp Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
        275                 280                 285             


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr 
    290                 295                 300                 


Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
305                 310                 315                 320 


Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Ala Asp Ser Val 
                325                 330                 335     


Lys Gly Arg Phe Thr Ile Thr Thr Asp Lys Ser Thr Ser Thr Ala Tyr 
            340                 345                 350         


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 
        355                 360                 365             


Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly 
    370                 375                 380                 


Thr Thr Val Thr Val Ser Ser Gly Glu Gly Thr Ser Thr Gly Ser Gly 
385                 390                 395                 400 


Gly Ser Gly Gly Ser Gly Gly Ala Asp Asp Ile Val Leu Thr Gln Ser 
                405                 410                 415     


Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys 
            420                 425                 430         


Arg Ala Ser Gln Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro 
        435                 440                 445             


Gly Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser 
    450                 455                 460                 


Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser 
465                 470                 475                 480 


Leu Thr Ile Asn Ser Leu Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys 
                485                 490                 495     


Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 
            500                 505                 510         


Glu Ile Lys 
        515 


